プログラム

The meeting is over. Thank you for your attendance and cooperation.
See you next time!!

Scientific Program

Day 1: Sat. 23rd Jan.

Japan Standard Time

Central European Time

Central Standard Time(USA)

Session / Lecture title

1/23 7:10

1/22 23:10

1/22 16:10

Opening remarks, KBCCC 2021

Presenter:	Takashi Inamoto

1/23 7:15

1/22 23:15

1/22 16:15

KBCCC 2021 highlights

Presenter:	Nobuhiko Shinkura
Chair:	Chikako Yamauchi

Special Lecture-1

1/23 7:30

1/22 23:30

1/22 16:30

Neoadjuvant therapy for Hormone receptor - negative PBC

Presenter:	Eric Winer (US)
Chair:	Shigeru Imoto

1/23 8:00

1/23 0:00

1/22 17:00

Lessons from I-SPY2: Current Results and Interpretations for Clinical Practice

Presenter:	Hope Rugo (US)
Chair:	Shinji Ohno

Sponsored Symposium-1
Co-organized with Chugai Pharmaceutical Co., Ltd.

1/23 8:30

1/23 0:30

1/22 17:30

Cancer Immunotherapy in Metastatic Triple-Negative Breast Cancer (mTNBC)

Presenter:	Sara Tolaney
Chair:	Tomoharu Sugie

50 min lecture and 10 min Q&As

1/23 9:40

1/23 1:40

1/22 18:40

Session-1: Local management for favorable responders to preoperative systemic therapy

Chairs:	Ismail Jatoi, Yuji Nakamoto, Hironobu Sasano （総合司会）

1/23 9:45

1/23 1:45

1/22 18:45

Diagnostic points of lesions during and after neoadjuvant therapy

Presenter:	Masako Kataoka
Chair:	Yuji Nakamoto

1/23 10:10

1/23 2:10

1/22 19:10

Individualized preoperative therapy to increase breast conserving rate; New approaches

Presenter:	Wonshik Han (South Korea)
Chair:	Hiromitsu Jinno

1/23 10:35

1/23 2:35

1/22 19:35

Radiation therapy after neoadjuvant therapy and new challenges for breast cancer

Presenter:	Michio Yoshimura
Chair:	Chikako Yamauchi

1/23 11:00

1/23 3:00

1/22 20:00

Breast cancer heterogeneity and inflmmation

Presenter:	Tatsuki Kataoka
Chair:	Hironobu Sasano

1/23 11:25

1/23 3:25

1/22 20:25

ctDNA application in breast cancer

Presenter:	Angel Rodriguez (US)
Chair:	Masahiro Kawashima

1/23 11:50

1/23 3:50

1/22 20:50

Issues to discuss

Presenter:	Ismail Jatoi (US)

1/23 12:15

1/23 4:15

1/22 21:15

Poster Presentation (on demand)

1/23 13:00

1/23 5:00

1/22 22:00

Plenary Lecture

Future perspective of cancer immunotherapy

Presenter:	Tasuku Honjo
Chair:	Masakazu Toi

Cancer tissue microenvironment controlling cancer immunity

Presenter:	Nagahiro Minato
Chair:	Takashi Inamoto

(30 mins lecture & 10 mins Q&As )

1/23 15:00

1/23 7:00

1/23 0:00

Session-2: Immuno-Oncology BC -Clinical advances

Chairs:	Shigehira Saji, Giuseppe Curigliano

1/23 15:05

1/23 7:05

1/23 0:05

Absolute Lymphocyte Count is a Predictor of Eribulin Efficacy for Advanced or Metastatic Breast Cancer in EMBRACE and Study 301

Presenter:	Yasuo Miyoshi
Chair:	Toshimi Takano

1/23 15:30

1/23 7:30

1/23 0:30

Novel approaches in the Immuno-Oncology therapy

Presenter:	Rebecca Dent (Singapore)
Chair:	Toshimi Takano

1/23 15:55

1/23 7:55

1/23 0:55

Neoadjuvant therapy with Immuno-Oncology agents

Presenter:	Giuseppe Curigliano (ITA)
Chair:	Shigehira Saji

1/23 16:20

1/23 8:20

1/23 1:20

Antiangiogenesis and PD-1 blockade

Presenter:	Qiang Liu (China)
Chair:	Eiji Suzuki

1/23 16:45

1/23 8:45

1/23 1:45

Alterlation of circulating immune profile in the Immuno-Oncology therapy

Presenter:	Kosuke Kawaguchi
Chair:	Hiroshi Ishiguro

1/23 17:10

1/23 9:10

1/23 2:10

Issues to discuss

Presenter:	Shigehira Saji

1/23 17:30

1/23 9:30

1/23 2:30

Voting

Chair:	Kosuke Kawaguchi

1/23 18:00

1/23 10:00

1/23 3:00

Session-3: Rissk Assessment, Management of patients with germline mutations

Chairs:	Koichiro Tsugawa, Akira Yamauchi, Masakazu Toi

1/23 18:05

1/23 10:05

1/23 3:05

Prediction tools to identify high-risk individuals

Presenter:	Masahiro Takada
Chair:	Wonshik Han (South Korea)

1/23 18:30

1/23 10:30

1/23 3:30

Should all newly diagnosed breast cancer patients have genetic testing

Presenter:	Stephen Grobmyer(UAE)
Chair:	Koichiro Tsugawa

1/23 18:55

1/23 10:55

1/23 3:55

Prevention of cancer development for women having pathogenic variants of hereditary breast cancer

Presenter:	Hideko Yamauchi
Chair:	Yutaka Yamamoto

1/23 19:20

1/23 11:20

1/23 4:20

Issues to discuss

Presenter:	Akira Yamauchi, Masakazu Toi

1/23 19:45

1/23 11:45

1/23 4:45

Voting

Presenter:	Masahiro Kawashima

1/23 20:30

1/23 12:30

1/23 5:30

Evening Lecture

Chair:	Kazuhiko Yamagami

1/23 20:35

1/23 12:35

1/23 5:35

New imaging and development of optimal screening system

Presenter:	Kenjiro Kimura
Chair:	Kazuhiko Yamagami

1/23 20:55

1/23 12:55

1/23 5:55

Dedicated breast PET imaging

Presenter:	Kanae Kawai Miyake
Chair:	Sadako Akashi-Tanaka

1/23 21:15

1/23 13:15

1/23 6:15

Surgical (or SNB) techniques for axilla in patients having neoadjuvant treatment

Presenter:	Stephen Grobmyer(UAE)
Chair:	Takayuki Kinoshita

1/23 22:00

1/23 14:00

1/23 7:00

Session-4: Radiation Therapy

Chairs:	Reshma Jagsi, Chikako Yamauchi, John Benson

1/23 22:05

1/23 14:05

1/23 7:05

The impact of COVID-19 on practice patterns of RT for breast cancer

Presenter:	Alice Ho(US)
Chairs:	Reshma Jagsi(US), Chikako Yamauchi

1/23 22:30

1/23 14:30

1/23 7:30

Regional node irradiation in Stage I-III breast cancer

Presenter:	Philip Poortmans(Belgium)
Chairs:	Reshma Jagsi(US), Chikako Yamauchi

1/23 22:55

1/23 14:55

1/23 7:55

Radiation therapy after neoadjuvant chemotherapy

Presenter:	Reshma Jagsi(US)
Chairs:	Reshma Jagsi(US), Chikako Yamauchi

1/23 23:20

1/23 15:20

1/23 8:20

Discussion

Presenter:	Reshma Jagsi(US)
Chairs:	Reshma Jagsi(US), Chikako Yamauchi

1/23 23:45

1/23 15:45

1/23 8:45

Voting

Chairs:	Reshma Jagsi(US), Chikako Yamauchi

Breast reconstruction and RT (on demand)

Presenter:	Reshma Jagsi(US)

Immunotherapy and RT (on demand)

Presenter:	Silvia Formenti(US)

Day 2: Sat. 6th Feb.

Japan Standard Time

Central European Time

Central Standard Time(USA)

Session / Lecture title

2/6 7:30

2/5 23:30

2/5 16:30

Sponsored Symposium-2
Co-organized with Novartis Pharma K.K.

Optimal sequential endocrine treatment with targeted therapies in postmenopausal ER-positive/HER2-negative advanced breast cancer

Presenter:	Yutaka Yamamoto
Chair:	Yasuo Miyoshi

2/6 8:00

2/6 0:00

2/5 17:00

Session-5: Optimization of breast cancer screening

Chairs:	Nobuhiko Shinkura, Masako Kataoka, Louis Chow

2/6 8:05

2/6 0:05

2/5 17:05

Breast cancer screening: Weighing the benefits and harms

Presenter:	Ismail Jatoi (US)
Chair:	Masako Kataoka

2/6 8:30

2/6 0:30

2/5 17:30

Breast cancer screening according to individual risk

Presenter:	Bruce Mann(AUS)
Chair:	Nobuhiko Shinkura

2/6 8:55

2/6 0:55

2/5 17:55

Risk and modality of screening

Presenter:	Louis Chow (HK)
Chair:	Nobuhiko Shinkura

2/6 9:20

2/6 1:20

2/5 18:20

Voting

Chair:	Yoshiaki Matsumoto

2/6 10:15

2/6 2:15

2/5 19:15

Symposium-2: Prediction of prognosis and benefits from chemotherapy

Chairs:	Hiroji Iwata, Takayuki Ueno

2/6 10:20

2/6 2:20

2/5 19:20

Sponsored lecture
Co-organized with Exact Sciences Corporation

Prediction of Prognosis and of Benefits from Chemotherapy

Presenter:	Virginia Kaklamani(US)
Chair:	Hiroji Iwata

2/6 10:45

2/6 2:45

2/5 19:45

Molecular assays for neoadjuvant therapy indication

Presenter:	Shigehira Saji
Chair:	Takayuki Ueno

2/6 11:10

2/6 3:10

2/5 20:10

Issues to discuss

Presenter:	Takayuki Ueno
Chair:	Shigehira Saji

2/6 11:35

2/6 3:35

2/5 20:35

Voting and discussion

Presenters:	Virginia Kaklamani, Shigehira Saji, Naomi Sakurai
Chair:	Nobuko Sakita-Kawaguchi

2/6 12:00

2/6 4:00

2/5 21:00

Sponsored Symposium-3
Co-organized with Eli Lilly Japan K. K.

Optimal use of CDK inhibitors in clinical practice

Presenter:	Rebecca Dent (Singapore)
Chair:	Takashi Ishikawa

Oral presentation

Discussants:	Shigenori Nagai, Tomoyuki Aruga, Jun-ichiro Watanabe

2/6 13:00

2/6 5:00

2/5 22:00

Discussants: Shigenori Nagai

Final results of the phase II clinical trial of the addition of dendritic cell vaccines to neoadjuvant chemotherapy in HER2 negative breast cancer patients (on demand)

Presenter:	Marta Santisteban

Outcomes of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: A retrospective single institution study (on demand)

Presenter:	Akane Higami

2/6 13:10

2/6 5:10

2/5 22:10

Discussants: Tomoyuki Aruga

Updated result of cisplatin-based preoperative chemotherapy for triple-negative breast cancer patients who did not achieve pCR (on demand)

Presenter:	Ayane Yamaguchi

Machine Learning methods for predicting response during and after neoadjuvant chemotherapy (on demand)

Presenter:	Jia Wang

2/6 13:20

2/6 5:20

2/5 22:20

Discussants: Jun-ichiro Watanabe

Usefulness of Dedicated breast PET in breast cancer treatment (on demand)

Presenter:	Takayuki Kadoya

2/6 13:30

2/6 5:30

2/5 22:30

Session-6: Immuno-Oncology BC -Tumor microenvironment

Moderator:	Dr. Hitoshi Tsuda, Dr. Stephen Fox

2/6 13:35

2/6 5:35

2/5 22:35

PD-L1 testing in breast cancer

Presenter:	Stephen Fox (AUS)
Chair:	Hitoshi Tsuda

2/6 14:00

2/6 6:00

2/5 23:00

Normalization of tumor vasculature and microenvironment

Presenter:	Dai Fukumura (US)
Chair:	Kosuke Kawaguchi

2/6 14:25

2/6 6:25

2/5 23:25

TIls in breast cancer: ready to use in daily practice?

Presenter:	Roberto Salgado (Belgium)
Chair:	Stephen Fox (AUS)

2/6 14:50

2/6 6:50

2/5 23:50

Voting

Chair:	Tomoharu Sugie

2/6 15:00

2/6 7:00

2/6 0:00

Session-7: Genomic profile and precision medicine in Asia

Chair:	Chikako Shimizu, Masakazu Toi

2/6 15:05

2/6 7:05

2/6 0:05

Insights into breast cancer in the East vs the West

Presenter:	Yoon Sim Yap (Singapore)
Chair:	Chikako Shimizu

2/6 15:30

2/6 7:30

2/6 0:30

Application of circulating tumor DNA analysis world-wide and in Japan

Presenter:	Steve Olsen
Chair:	Masakazu Toi

2/6 15:55

2/6 7:55

2/6 0:55

Establishing and implementing cancer genomic medicine in Japan

Presenter:	Tatsunori Shimoi

2/6 16:20

2/6 8:20

2/6 1:20

Discussion

Panelists:	Chikako Shimizu, Yoon Sim Yap, Steve Olsen, Masashi Kanai, Masakazu Toi, Nobuko Sakita-Kawaguchi

2/6 16:30

2/6 8:30

2/6 1:30

Sponsored Symposium-4
Co-organized with Pfizer Japan Inc.

Role of cyclin-dependent kinases 4/6 inhibitors created in the treatment of HR+/HER2-metastatic breast cancer

Presenter:	Giuseppe Curigliano(ITA)
Chair:	Shinji Ohno

2/6 17:30

2/6 9:30

2/6 2:30

Session-8: Local management for favorable responders to preoperative systemic therapy, and panel discussion

Chairs:	Chiun Shen Huang (TWN), Kazuhiko Yamagami

2/6 17:35

2/6 9:35

2/6 2:35

Favorable responders after chemo:the best diagnosis and surgical management

Presenter:	Emiel Rutgers(NLD)
Chair:	Seigo Nakamura

2/6 18:00

2/6 10:00

2/6 3:00

When is it safe to omit breast/axillary surgery

Presenter:	John Benson(UK)
Chair:	Chiun Shen Huang (TWN)

2/6 18:45

2/6 10:45

2/6 3:45

Special Lecture-2

EBCTCG meta analysis

Presenter:	Richard Gray (UK)
Chair:	Masakazu Toi

2/6 19:30

2/6 11:30

2/6 4:30

Biomarker for neoadjuvant/adjuvant hormone therapy

Presenter:	John Robertson (UK)
Chair:	Takashi Ishikawa

2/6 20:30

2/6 12:30

2/6 5:30

Role of Adjuvant oral FU for HER2-negative BC

Presenter:	Masakazu Toi
Chair:	John Robertson

2/6 21:30

2/6 13:30

2/6 6:30

Consensus session

Chairs:	John Benson, Chikako Yamauchi, Ismail Jatoi, Masakazu Toi, Takashi Inamoto

Post-neoadjuvant local therapy

Chair:

Biomarkers/ genomics

Chair:	Hope Rugo (US)

Screening

Chair:	Ismail Jatoi (US)

Voting

Chair:	Masahiro Takada

2/6 24:00

2/6 16:00

2/6 9:00

Closing

Masakazu Toi

京都乳癌研究ネットワーク(KBCRN)

The meeting is over. Thank you for your attendance and cooperation. See you next time!!